10-Q: Myomo Reports Wider Q2 Loss Amid Revenue Growth

Myomo, Inc. reported a significant increase in net loss for the second quarter and first half of 2025 despite substantial revenue growth, driven by higher operating expenses and a decline in gross margin.

Summary

• Revenue for the six months ended June 30, 2025, increased by 73% to $19.48 million, up from $11.28 million in the same period of 2024.
• Net loss for the six months ended June 30, 2025, widened to $8.10 million, compared to a net loss of $4.96 million for the six months ended June 30, 2024.
• Gross profit increased by 66% to $12.66 million for the six months ended June 30, 2025, from $7.62 million in the prior year period.
• Gross margin decreased to 65.0% for the six months ended June 30, 2025, down from 67.6% in the same period of 2024, primarily due to higher material costs and increased manufacturing overhead.
• Cash used in operating activities significantly increased to $11.54 million for the six months ended June 30, 2025, compared to $5.16 million in the prior year period.
• Cash and cash equivalents stood at $14.24 million as of June 30, 2025, a decrease from $24.37 million at December 31, 2024.
• Accounts receivable, net, increased to $7.05 million as of June 30, 2025, from $3.83 million at December 31, 2024, partly due to a payment hold by a Medicare Administrative Contractor.
• Research and development expenses increased by 93% to $3.79 million for the six months ended June 30, 2025, due to higher payroll and outside engineering services.
• Selling, clinical, and marketing expenses increased by 87% to $9.63 million for the six months ended June 30, 2025, driven by increased headcount and advertising spending.
• General and administrative expenses increased by 33% to $7.35 million for the six months ended June 30, 2025, due to increased payroll costs in reimbursement functions and stock-based compensation.
• CMS represented 58% of total revenues for the six months ended June 30, 2025, highlighting significant revenue concentration.
• The company drew $2.5 million from its revolving line of credit and $1.5 million from its term loan facility during the three months ended June 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significantly widened net loss, increased cash burn, and a decline in gross margin, despite strong revenue growth. The identified material weakness in internal controls and ongoing reimbursement challenges with Medicare Advantage plans add to the concerns. While liquidity is stated to be sufficient for 12 months, the rate of cash consumption is high, and future profitability remains uncertain.

Positives

• Revenue grew substantially by 73% for the six months ended June 30, 2025, indicating strong demand for MyoPro products.
• Gross profit increased by 66% for the six months ended June 30, 2025, demonstrating increased sales volume.
• The company successfully secured additional debt financing, drawing $2.5 million from its revolving line of credit and $1.5 million from its term loan facility, enhancing liquidity.
• Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next twelve months.
• Introduction of the enhanced MyoPro 2X on April 30, 2025, indicates continued product innovation.

Negatives

• Net loss significantly widened to $8.10 million for the six months ended June 30, 2025, from $4.96 million in the prior year, indicating increased unprofitability.
• Cash used in operating activities more than doubled to $11.54 million for the six months ended June 30, 2025, reflecting a higher cash burn rate.
• Gross margin decreased to 65.0% from 67.6% for the six months ended June 30, 2025, due to higher material costs and increased manufacturing overhead.
• Cash and cash equivalents decreased by over $10 million from December 31, 2024, to June 30, 2025.
• Working capital decreased from $22.62 million at December 31, 2024, to $16.29 million at June 30, 2025.
• A material weakness in internal control over financial reporting was identified as of December 31, 2024, related to IT general controls, which has not yet been fully remediated.

Risks

• Ability to achieve or obtain sufficient reimbursement from third-party payers for products remains a significant challenge.
• Dependence upon external sources for financing operations, especially if cash flow breakeven is not achieved or maintained.
• Revenue concentration with Medicare and a particular insurance payer poses a risk if reimbursement policies change or are restricted.
• Medicare Advantage plans have been reducing MyoPro authorizations since the second half of 2024, negatively impacting revenues.
• CMS pre-payment audits on MyoPro claims, with some denials for medical necessity documentation, could impact future reimbursements.
• Changes by direct-to-consumer advertising companies in reaching prospective patients could adversely impact lead generation and increase advertising costs.
• Significant political, trade, regulatory developments, including tariffs or changes in U.S. trade policies, could materially affect financial condition.
• Inability to obtain additional funds on reasonable terms if required to achieve operating cash flow breakeven.
• Usage of line of credit and term loan facility is subject to financial and operating covenants, which could limit operations and liquidity.
• Failure to obtain broad coverage policies or more restrictive coverage requirements from Medicare or third-party payers could significantly constrain sales.
• There is no assurance that final CMS fees will be sufficient to permit profitable operations.
• Increased production costs may outpace increases in reimbursement levels, further impacting profitability.
• Failure to operate profitably could negatively impact market acceptance of MyoPro.

Future Outlook

Management plans to invest in increasing demand and capacity for its direct billing channel and to increase revenues in the U.S. O&P channel in 2025. Research and development, selling, clinical, marketing, and general and administrative expenses are all expected to increase annually as the company invests in product enhancement, advertising, and reimbursement capacity. The company believes its current cash and investments will fund operations for at least the next twelve months.

Management Comments

• "Our plan for 2025 is to invest in increasing demand and adding capacity to support our direct billing channel, while making investments to increase revenues in the U.S. O&P channel."
• "We intend to invest in enhancing our existing products in 2025 and expect R&D costs to increase on an annual basis."
• "We expect SC&M expenses to increase in 2025 as we increase our advertising spending and clinical capacity to grow revenues in our direct billing channel."
• "We expect that G&A expenses will increase in 2025 as a result of increasing our reimbursement capacity in order to grow revenue in the direct billing channel."
• "We believe that our existing cash, cash equivalents, short-term investments and restricted cash at June 30, 2025 will be sufficient to fund our operations for the next twelve months from the date of this report."

Industry Context

The company operates in the wearable medical robotics sector, specifically targeting neuromuscular disorders with its MyoPro orthosis. The industry is characterized by reliance on third-party payer reimbursement, which is subject to evolving regulations and utilization management efforts by insurers. The company's focus on direct billing and navigating complex reimbursement landscapes, particularly with Medicare and Medicare Advantage plans, reflects a broader trend in the medical device industry to manage revenue cycles and patient access directly. Increased R&D and marketing spending are common for companies seeking to expand market penetration and introduce new product versions in competitive medical technology markets.

Comparison to Industry Standards

• The company's gross margin of 65.0% for the six months ended June 30, 2025, while strong, saw a decline from 67.6% in the prior year, which could indicate increasing cost pressures or a shift in product mix compared to industry peers in specialized medical devices.
• The significant increase in cash used in operating activities ($11.54 million vs. $5.16 million) suggests a higher burn rate than typically seen in mature, profitable medical device companies, aligning more with growth-stage companies heavily investing in scaling operations and market penetration.
• The reliance on Medicare (58% of H1 2025 revenue) and the challenges with Medicare Advantage authorizations highlight the unique regulatory and reimbursement hurdles faced by companies in the durable medical equipment and orthotics space, which can be more pronounced than for pharmaceutical or less specialized device companies.
• The identified material weakness in IT general controls is a significant concern, as robust internal controls are a standard expectation across all publicly traded companies, especially those handling sensitive patient and financial data. This contrasts with best practices for corporate governance and financial reporting integrity.

Corporate Governance

Legal Proceedings

• No material claims, assessments, or litigation against the company as of June 30, 2025.

Stakeholder Impact

• **Shareholders**: Face increased dilution risk from potential future equity raises due to ongoing losses and high cash burn. The widening net loss and declining gross margin could negatively impact share price.
• **Patients**: Benefit from continued product innovation (MyoPro 2X) and increased clinical capacity, but face potential challenges with insurance reimbursement, particularly from Medicare Advantage plans and ongoing CMS audits.
• **Employees**: Increased headcount in clinical, reimbursement, and manufacturing functions indicates growth opportunities, but the material weakness in internal controls could impact operational efficiency and compliance.
• **Creditors**: The company has drawn on its credit facilities and is in compliance with covenants, but continued high cash burn and losses could increase credit risk if profitability is not achieved.
• **Suppliers**: Increased manufacturing overhead and material costs suggest continued demand for components, but the company's financial health will influence long-term supplier relationships.

Next Steps

• Continue to invest in increasing demand and adding capacity for the direct billing channel.
• Make investments to increase revenues in the U.S. O&P channel.
• Invest in enhancing existing products and accelerating new product development, leading to increased R&D spending.
• Increase advertising spending and clinical capacity to grow revenues in the direct billing channel.
• Increase reimbursement capacity to serve Medicare Part B patients, leading to increased G&A expenses.
• Continue to refine and enhance controls to remediate the material weakness in internal control over financial reporting, including formalizing user provisioning, change management, and review of third-party SOC reports.

Key Dates

Recommendation

While Myomo demonstrates strong revenue growth and product innovation, the significant increase in net loss and cash burn, coupled with a declining gross margin, raises concerns about its path to profitability. The identified material weakness in internal controls and ongoing reimbursement challenges with Medicare Advantage plans add to the operational risks. The company's liquidity is stated to be sufficient for 12 months, but the current trajectory suggests a need for further capital or a significant improvement in operational efficiency. A 'hold' recommendation is appropriate, advising investors to monitor the company's ability to control costs, improve margins, and successfully navigate reimbursement complexities before considering further investment.

Keywords

MyoPro, myoelectric orthotics, wearable robotics, neuromuscular disorders, SEC filing, 10-Q, financial results, medical devices, reimbursement, Medicare, cash flow, operating loss, liquidity, corporate governance, risk factors